Journal of Hepatology, 1991; 12: 409-412 Elsevier Science Publishers B.V . 0168-8278/91/$03.50 © 1991 Author Index (Vol. 12) Abraham, N.G., see Sacerdoti, D., 230 Bode, Ch., see Fukui, H., 162 Lenzi, M., Volta, U., Zauli, D. and Bi- Adams, D. and Neuberger, J., Graft rejec- Bode, J.Ch., see Fukui, H., 162 anchi, F.B., Anti-HCV antibodies de- tion following liver transplantation, 126 Bonino, F., see Salassa, B., 10 tected by ELISA in autoimmune and Albert, A., Diagnosis of hepatitis C. Facts Bortolotti, F., Tagger, A., Cadrobbi, P., cryptogenic chronic liver disease, 269 and perspectives, 279 Crivellaro, C., Pregliasco, F., Ribero, Castrignano, R., see Floreani, A., 217 Alberti, A., see Bortolotti, F., 176 M.L. and Alberti, A., Antibodies to Catalano, D., see Caruso, G., 262 Alberti, A., see Levrero, M., 60 hepatitis C virus in community-acquired Cataldi, A., see Barreca, T., 40 Alberti, A., see Pontisso, P., 203 acute non-A, non-B hepatitis, 176 Chao, Y., see Lee, F.-Y., 236 Albores-Saavedra, J., see Silva, M.O., 318 Bouffard, P., see Zoulim, F., 150 Charneau, J., see Rossi, V., 283 Alexander, G., see Rolando, N., 1 Boyer, J., see Rossi, V., 283 Chemello, L., see Pontisso, P., 203 Alexander, G.J.M., see Naoumov, N.V., Brahm, J., see Rolando, N., 1 Chevallier, M., see Krawitt, E.L., 190 382 Braillon, A., see Lee, S.S., 157 Chiaberge, E., see Salassa, B., 10 Alexander, G.J.M., see Sheron, N., 241 Bramato, C., see Salassa, B., 10 Chiaramonte, M., see Farinati, F., 402 Amouretti, M., see Pelletier, G., 327 Brauner, B., see Fukui, H., 162 Chiaramonte, M., see Floreani, A., 217 Andersen, T., Gluud, C., Franzmann, Brechot, C., see Nalpas, B., 70 Chiu, K.-W., see Liaw, Y.-F., 106 M.-B. and Christoffersen, P., Hepatic Brisigotti, M., see Callea, F., 372 Chossegros, P., see Krawitt, E.L., 190 effects of dietary weight loss in morbidly Brissot, P., Jacquelinet, C., Jouanolle, H., Christoffersen, P., see Andersen, T., 224 obese subjects, 224 David, V., Guyader, D., Guéguen, M., Christoffersen, P., see Junge, J., 83 Andrzejewski, W., see Lukomska, B., 332 Blayau, M., Lescoat, G., Messner, M. Chu, C.-M., see Liaw, Y.-F., 106 Aréjola, J.M., see Quiroga, J., 302 and Deugnier, Y., Short-term predni- Clementi, C., see Taliani, G., 264 Avantaggiati, M.L., see Levrero, M., 60 solone followed by recombinant human Collet, D., see Pelletier, G., 327 a-interferon alone or combined with ad- Colletta, C., see Pontisso, P., 203 Ballardini, G., see Cassani, F., 269 enine-arabinoside in chronic hepatitis B. Colombel, J.F., Vaerman, J.P., Mesnard, Balsano, C., see Levrero, M., 60 A prospective and randomized trial, 181 B., Dehennin, J.D., Dive, C. and Ram- Baraldini, M., see Bernardi, M., 207 Brunetto, M.R., see Salassa, B., 10 baud, J.C., Jenunal immunoglobulin se- Barreca, T., Franceschini, R., Cataldi, A. Budillon, G., see Cuomo, R., 87 cretion in alcoholic patients with and and Rolandi, E., Plasma somatostatin Burtin, P., see Calés, P., 263 without cirrhosis, 145 response to an oral mixed test meal in Burtin, P., see Rossi, V., 283 Colombo, P., Di Blasi, F., Magrin, S., Fa- cirrhotic patients, 40 biano, C., Di Marco, V., D’Amelio, L., Baruch, Y., Frith, L.O. and Kirsh, R.E., Cadrobbi, P., see Bortolotti, F., 176 Lojacono, F., Spinelli, G. and Caraxi, Twenty-one percent partial hepatecto- Callard, P., see Trinchet, J.-C. , 139 A., Smouldering hepatitis B virus repli- my. In vivo rat model for the study of Calés, P., Burtin, P. and Oberti, F., Spon- cation in patients with chronic liver dis- liver regeneration, 316 taneous regression of esophageal varices ease and hepatitis delta virus superinfec- Baxter, J.N., see Jenkins, S.A., 296 is a phenomenon that has spontaneously tion, 64 Beaugrand, M., see Mal, F., 45 disappeared from our memory, 263 Coltorti, M., see Caporaso, N., 367 Beaugrand, M., see Trinchet, J.-C., 139 Calés, P., see Rossi, V., 283 Costa, V., see Faa, G., 14 Bendahou, M., see Mal, F., 45 Callea, F., Brisigotti, M., Faa, G., Lucini, Costan, G., see Jaramillo, J.L., 100 Bendtsen, F., Schifter, S. and Henriksen, L. and Eriksson, S., Identification of PiZ Crivellaro, C., see Bortolotti, F., 176 J.H., Increased circulating calcitonin gene products in liver tissue by a mono- Csomés, G., see Nassuato, G., 290 gene-related peptide (CGRP) in cirrho- clonal antibody specific for the Z mutant Cuomo, R., Rodino, S., Rizzoli, R., Si- sis, 118 of a,-antitrypsin, 372 moni, P., Roda, E., Cantoni, L., Rizzar- Benhamou, J.P., see Denninger, M.H., Cancellieri, C., see Bernardi, M., 207 dini, M., De Rosa, G., Le Grazie, C., Di 261 Cantoni, L., see Cuomo, R., 87 Padova, C. and Budillon, G., Bile and Berg, P.A., see Klein, R., 21 Caporaso, N., Romano, M., Marmo, R., biliary lipid secretion in rats with hexa- Berk, L., De Man, R.A., Schalm, S.W., De Sio, I., Morisco, F., Minerva, A. and chlorobenzene-induced porphyria. Ef- Labadie, R.P. and Heijtink, R.A., Ben- Coltarti, M., Hepatitis C infection is an fect of S-adenosyl-L-methionine admin- eficial effects of Phyllanthus amarus for additive risk factor for development of istration, 87 chronic hepatitis B, not confirmed, 405 hepatocellular carcinoma in patients Bernardi, M., Rubboli, A., Trevisani, F., with cirrhosis, 367 D’Amelio, L., see Colombo, P., 64 Cancellieri, C., Ligabue, A., Baraldini, Capdeville, R., see Pelletier, G., 334 D’Angelo, A., see Floreani, A., 217 M. and Gasbarrini, G., Reduced cardio- Caraxi, A., see Colombo, P., 64 D’Aubigny, N., see Rossi, V., 283 vascular responsiveness to exercise-in- Carithers, R.L., Jr., see Shiffman, M.L., Daniels, H., see Sheron, N., 241 duced sympathoadrenergic stimulation 351 Daniels, H.M., see Naoumov, N.V., 382 in patients with cirrhosis, 207 Carnot, F., see Tran, A., 36 David, V., see Brissot, P., 181 Berris, B., see Feinman, S.V., 377 Caroli, F.-X., see Pelletier, G., 327 Davies, S.E., see Kalayci, C., 54 Berthelot, P., see Nalpas, B., 70 Carreno, V., see Ruiz-Moreno, M., 265 Daziano, E., see Salassa, B., 10 Berthelot, P., see Tran, A., 36 Caruso, G. and Catalano, D., Esophageal De Bac, C., see Taliani, G., 264 Bianchi, F.B., see Cassani, F., 269 varices and hepato-pulmonary syn- De Groote, J., see Faa, G., 75 Bianchi, G., see Marchesini, G., 267 drome in liver cirrhosis, 262 De Ley, M., see Volpes, R., 195 Blayau, M., see Brissot, P., 181 Casewell, M., see Rolando, N., 1 De Man, R.A., see Berk, L., 405 Boboc, B., see Tran, A., 36 Cassani, F., Ballardini, G., Fusconi, M., De Maria, N., see Farinati, F., 402 410 De Marzio, E., see Levrero, M., 60 Fagan, E.A., see Deakin, C.D., 251 Hartmann, D.J., see Trinchet. J.-C. , 139 De Rosa, G., see Cuomo, R., 87 Fagiulo, S., see Farinati, F., 402 Harvey, F., see Rolando, N., 1 De Sio, I., see Caporaso, N., 367 Farinati, F., De Maria, N., Chiaramonte, Heijtink, R.A., see Berk, L., 405 De Sousa, J.M.M., Portmann, B. and Wil- M., Fagiulo, S., Salvagnini, M. and Nac- Henriksen, J.H., see Bendtsen, F., 118 liams, R., Nodular regenerative hyper- carato, R., Hormonal treatment of hep- Herrick, A.L., Moore, M.R., Thompson, plasia of the liver and the Budd-Chiari atocellular carcinoma, 402 G.G., Ford, G.P. and McColl, K.E.L., syndrome. Case report, review of the Feinman, S.V., Berris, B. and Herst, R., Cholelithiasis in patients with variegate literature and reappraisal of pathogene- Anti-HCV in post-transfusion hepatitis: porphyria, 50 sis, 28 deductions from a prospective study, 377 Herst, R., see Feinman, S.V., 377 De Vos, R., see Faa, G., 75 Fernandez, J.A., see Silva, M.O., 312 Hilden, J., see Malchow-Moller, A., 321 De Vos, R., see Volpes, R., 195 Fevery, J., see Faa, G., 75 Horn, T., see Junge, J., 83 De la Mata, M., see Jaramillo, J.L., 100 Fintelmann, V., see Klein, R., 21 Housset, C., see Nalpas, B., 70 DeCarli, L.M., see Lieber, C.S., 394 Fischer, G., see Kleber, G., 362 Housset, C., see Tran, A., 36 Deakin, C.D., Fagan, E.A. and Williams, Fischer-Nielsen, A., Poulsen, H.E., Han- Huu, T.P., see Mal, F., 45 R., Cytoprotective effects of calcium sen, B.A., Hage, E. and Keiding, S., channel blockers. Mechanisms and po- CCl, cirrhosis in rats: irreversible histo- Iemmolo, R.M., see Nassuato, G., 290 tential applications in hepatocellular in- logical changes and differentiated func- Iqbal, S., Elcombe, C.R. and Elias, E., jury, 251 tional impairment, 110 Maintenance of mixed-function oxidase Deana, R., see Nassuato, G., 290 Floreani, A., Chiaramonte, M., Giannini, and conjugation enzyme activities in Degos, F., see Denninger, M.H.., 261 S., Malvasi, L., Lodetti, M.G., Castrig- hepatocyte cultures prepared from nor- Degott, C., see Denninger, M.H., 261 nano, R., Giacomino, A., D’Angelo, A. mal and diseased human liver, 336 Dehennin, J.D., see Colombel, J.F., 145 and Naccarato, R., Longitudinal study Delmont, J., see Pelletier, G., 327 on osteodystrophy in primary biliary cir- Jacerdoti, D., Merkel, C. and Gatta, A., Demelia, L., see Faa, G., 14 rhosis (PBC) and a pilot study in calcito- Importance of 1-month-effect of nadolol Denninger, M.H., Degos, F., Poilane, I., nin treatment, 217 on portal pressure in predicting failure of Degott, C., Benhamou, J.P. and Guillin, Ford, G.P., see Herrick, A.L., 50 prevention of rebleeding in cirrhosis, 124 M.C., Plasma level of vitamin K-depen- Fragasso, A., see Nassuato, G., 290 Jacquelinet, C., see Brissot, P., 181 dent clotting factors as marker for hep- Franceschini, R., see Barreca, T., 40 Jaramillo, J.L., De La Mata, M., Mino, atocellular carcinoma, 261 Francesconi, M.A., see Nassuato, G., 290 G., Costan, G. and Gémez-Camacho, Depla, E., see Volpes, R., 195 Franzmann, M.-B., see Andersen, T., 224 F., Somatostatin versus Sengstaken ball- Desmet, V.J., see Faa, G., 14 Frith, L.O., see Baruch, Y., 316 oon tamponade for primary haemostasia Desmet, V.J., see Faa, G., 75 Fukui, H., Brauner, B., Bode, J.Ch. and of bleeding esophageal varices. A ran- Desmet, V.J., see Volpes, R., 195 Bode, Ch., Plasma endotoxin concentra- domized pilot study, 100 Deugnier, Y., see Brissot, P., 181 tions in patients with alcoholic and non- Jaser, N., see Jenkins, S.A., 296 Dhumeaux, D., see Mallat, A., 275 alcoholic liver disease: reevaluation with Jenkins, S.A., Shields, R., Jaser, N., El- Di Blasi, F., see Colombo, P., 64 an improved chromogenic assay, 162 lenbogen, S., Makin, C., Naylor, E., Di Marco, V., see Colombo, P., 64 Funaki, N., see Tanaka, Y., 344 Nestead, M. and Baxter, J.N., The man- Di Padova, C., see Cuomo, R., 87 Furlan, C., see Taliani, G., 264 agement of gastrointestinal haemor- Diodati, G., see Levrero, M., 60 Fusconi, M., see Cassani, F., 269 rhage by somatostatin after apparently Diop, D., see Levrero, M., 60 successful endoscopic injection sclero- Dive, C., see Colombel, J.F., 145 Garbe, W., see Klein, R., 21 therapy for bleeding oesophageal vari- Dong, J.-T., see Liaw, Y.-F., 106 Garnier, M., see Mal, F., 45 ces, 296 Driss, F., see Nalpas, B., 70 Gasbarrini, G., see Bernardi, M., 207 Johnson, P.J., see Kalayci, C., 54 Gatta, A., see Jacerdoti, D., 124 Jouanolle, H., see Brissot, P., 181 Eddleston, A., see Sheron, N., 241 Gatta, A., see Sacerdoti, D., 230 Joubaud, F., see Rossi, V., 283 Elcombe, C.R., see Iqbal, S., 336 Geigenberger, G., see Kleber, G., 362 Juhl, E., see Malchow-Moller, A., 321 Elias, E., see Iqbal, S., 336 Gerard, F., see Krawitt, E.L., 190 Junge, J., Horn, T., Vyberg, M., Christof- Ellenbogen, S., see Jenkins, S.A., 296 Giacomini, A., see Floreani, A., 217 fersen, P. and Svendsen, L.B., The pat- Eriksson, S., see Callea, F., 372 Giannini, S., see Floreani, A., 217 tern of fibrosis in the acinar zone 3 areas Erlinger, S., see Pelletier, G., 327 Girod, C., see Lee, S.S., 157 in early alcoholic liver disease, 83 Escalante, B.A., see Sacerdoti, D., 230 Gluud, C., see Andersen, T., 224 Etienne, J.-P., see Pelletier, G., 327 Gmelin, K., see Kallinowski, B., 404 Kalayci, C., Johnson, P.J., Davies, S.E. Goka, J., see Sheron, N., 241 and Williams, R., Hepatitis B virus re- Faa, G., Van Eyken, P., De Vos, R., Fev- G6émez-Camacho, F., see Jaramillo, J.L., lated hepatocellular carcinoma in the ery, J.,. Van Damme, B. De Groote, J. 100 non-cirrhotic liver, 54 and Desmet, V.J., Light chain deposi- Gronvall, S., see Malchow-Moller, A., 321 Kallinowski, B., Theilmann, L., Gmelin, tion disease of the liver associated with Guarner, F., see Quiroga, J., 302 K., Rambausek, M., Mohring, M. and AL-type amyloidosis and severe chole- Guillin, M.C., see Denninger, M.H., 261 Kommerell, B., Incidence and preva- stasis. A case report and literature re- Guivarc’h, M., see Pelletier, G., 327 lence of antibodies to hepatitis C virus view, 75 Guivarch, P., see Pelletier,G. , 327 kidney transplanted patients, 404 Faa, G., Van Eyken, P., Demelia, L., Val- Guyader, D., see Brissot, P., 181 Keiding, S., see Fischer-Nielsen, A., 110 lebona, E., Costa, V. and Desmet, V.J., Guéguen, M.., see Brissot, P., 181 Kim, C.-i., see Tanaka, Y., 344 Idiopathic adulthood ductopenia pre- Kirsch, R.E., see Baruch, Y., 316 senting with chronic recurrent chole- Hadengue, A., see Lee, S.S., 157 Kleber, G., Sauerbruch, T., Fischer, G., stasis. A case report, 14 Hage, E., see Fischer-Nielsen, A., 110 Geigenberger, G. and Paumgartner, G., Faa, G., see Callea, F., 372 Hakim, J., see Mal, F., 45 Reduction of transmural oesophageal Fabiano, C., see Colombo, P., 64 Hamelin, B., see Nalpas, B., 70 variceal pressure by metoclopramide, 362 Fagan, E., see Rolando, N., 1 Hansen, B.A., see Fischer-Nielsen, A., 110 Klein, R., Kloppel, G., Garbe, W., Fin- 411 telmann, V. and Berg, P.A., Antimito- Lo, K.-J., see Lee, S.-D., 246 infection in hepatocellular carcinoma chondrial antibody profiles determined Lodetti, M.G., see Floreani, A., 217 and alcoholic liver disease, 70 at early stages of primary biliary cirrho- Lojacono, F., see Colombo, P., 64 Naoumov, N.V., Lau, J.Y.N., Daniels, sis differentiate between a benign and a Lucini, L., see Callea, F., 372 H.M., Alexander, G.J.M. and Williams, progressive course of the disease. A Lukomska, B., Pienkowska, B., Andrze- R., Detection of HBV-DNA using a dig- retrospective analysis of 76 patients over jewski, W. and Olszewski, W.L., Liver oxigenin-labelled probe: A rapid tech- 6-18 years, 21 sinusoidal cytotoxic cells are recruited nique without loss of sensitivity, 382 Kléppel, G., see Klein, R., 21 from blood and divide locally, 332 Nassuato, G., Iemmolo, R.M., Strazza- Kommerell, B., see Kallinowski, B., 404 bosco, M., Lirussi, F., Deana, R., Fran- Krawitt, E.L., Zannier, A., Chossegros, Magrin, S., see Colombo, P., 64 cesconi, M.A., Muraca, M., Passera, P., Gerard, F., Chevallier, M., Mutin, Mak, K.M., see Tanaka, Y., 344 D., Fragasso, A., Orlando, R., Csomés, M., Trepo, C. and Touraine, J.-L., Ex- Makin, C., see Jenkins, S.A., 296 G. and Okolicsanyi, L., Effect of Silibi- pression of HLA antigens and T cell in- Mal, F., Huu, T.P., Bendahou, M., Trin- nin on biliary lipid composition. Experi- filtrates in chronic viral hepatitis. A com- chet, J.C., Garnier, M., Hakim, J. and mental and clinical study, 290 parison of biopsy and fine-needle aspi- Beaugrand, M., Chemoattractant and Natoli, G., see Levrero, M., 60 ration findings, 190 opsonic activity in ascitic fluid. A study Naylor, E., see Jenkins, S.A., 296 in 47 patients with cirrhosis or malignant Nestead, M., see Jenkins, S.A., 296 Laarif, M., see Trinchet, J.-C., 139 peritonitis, 45 Neuberger, J., see Adams, D., 126 Labadie, R.P., see Berk, L., 405 Malchow-Mgller, A., Grgnvall, S,, Hil- Labarga, P., see Quiroga, J., 170 den, J., Juhl, E., Lassen, A., Matzen, Oberti, F., see Calés, P., 263 Lai, K.H., see Lee, F.-Y., 236 P., Mindeholm, L., Stockholm, K.H., Okolicsanyi, L., see Nassuato, G., 290 Lamelin, J.P., see Zoulim, F., 150 Thomsen, C. and Witt, K., Ultrasound Olszewski, W.L., see Lukomska, B., 332 Lassen, A., see Malchow-Moller, A., 321 examination in jaundiced patients: Is Orlando, R., see Nassuato, G., 290 Lau, J., see Sheron, N., 241 computer-assisted preclassification help- Otte, J.B., Recent developments in liver Lau, J.Y.N., see Naoumov, N.V., 382 ful, 321 transplantation. Lessons from a 5-year Lavarini, C., see Salassa, B., 10 Mallat, A. and Dhumeaux, D., Cocaine experience, 386 Le Grazie, C., see Cuomo, R., 87 and the liver, 275 Lebrec, D., see Lee, S.S., 157 Malvasi, L., see Floreani, A., 217 Paintaud, G. and Miguet, J.P., Diagnostic Lecce, R., see Taliani, G., 264 Manns, M., see Ruiz-Moreno, M., 265 tools in liver allograft rejection, 256 Lee, F.-Y., Lee, S.-D., Tsai, Y.-T., Lai, Marchesini, G., Bianchi, G. and Zoli, M., Passera, D., see Nassuato, G., 290 K.H., Chao, Y., Lin, H.-C., Wang, S.-S. Oral BCAA in the treatment of chronic Pateron, D., see Trinchet, J.-C., 139 and Lo, K.-J., A randomized controlled hepatic encephalopathy, 267 Paumgartner, G., see Kleber, G., 362 trial of quinidine in the treatment of cir- Marmo, R., see Caporaso, N., 367 Pelletier, G., Delmont, J., Capdeville, R., rhotic patients with muscle cramps, 236 Matzen, P., see Malchow-Moller, A., 321 Mosnier, H., Raymond, J.-M., Collet, Lee, S.-D., Tong, M.J., Wu, J.-C., Lin, McColl, K.E.L., see Herrick, A.L., 50 D., Caroli, F.-X., Moreaux, J., Gui- H.-C., Tsai, Y.-T. and Lo, K.-J., A ran- McGiff, J.C., see Sacerdoti, D., 230 varc’h, M., Amouretti, M., Perissat, J., domised double-blind placebo-controlled Merkel, C., see Jacerdoti, D., 124 Guivarch, P., Erlinger, S. and Etienne, trial of prednisolone therapy in HBeAg Mesnard, B., see Colombel, J.F., 145 J.-P., Treatment of gallstones with pie- and HBV DNA positive Chinese pa- Messner, M.., see Brissot, P., 181 zoelectric lithotripsy and oral bile acids. tients with chronic active hepatitis B, 246 Meyer zum Biischenfelde, K.-H., see A multicenter study, 327 Lee, S.-D., see Lee, F.-Y., 236 Rieder, H., 268 Perissat, J., see Pelletier, G., 327 Lee, S.S., Hadenuye, A., Girod, C., Brail- Meyer zum Biischenfelde, K.-H., see Ruiz- Person, B., see Rossi, V., 283 lon, A. and Lebrec, D., Divergent circu- Moreno, M., 265 Pessione, E., see Salassa, B., 10 latory effects of betaxolol in conscious Miguet, J.P., see Paintaud, G., 256 Philpott-Howard, J., see Rolando, N., 1 and anesthetized normal and portal hy- Milazzo, A., see Quiroga, J., 170 Pichoud, C., see Zoulim, F., 150 pertensive rats, 157 Mindeholm, L., see Malchow-Moller, A., Pienkowska, B., see Lukomska, B., 332 Lenzi, M., see Cassani, F., 269 321 Poilane, I., see Denninger, M.H., 261 Lecoat, G., see Brissot, P., 181 Minerva, A., see Caporaso, N., 367 Pol, S., see Nalpas, B., 70 Levrero, M., Tagger, A., Balsano, C., De Mino, G., see Jaramillo, J.L., 100 Pontisso, P., Morsica, G., Ruvoletto, Marzio, E., Avantaggiati, M.L., Natoli, Mohring, M., see Kallinowski, B., 405 M.G., Zambello, R., Colletta, C., Che- G., Diop, D., Villa, E., Diodati, G. and Moore, E.W., see Shiffman, M.L., 351 mello, L. and Alberti, A., Hepatitis B vi- Alberti, A., Antibodies to hepatitis C vi- Moore, M.R., see Herrick, A.L., 50 rus binds to peripheral blood mononu- rus in patients with hepatocellular carci- Moreaux, J., see Pelletier, G. , 327 clear cells via the pre S1 protein, 203 noma, 60 Morsica, G., see Pontisso, P., 203 Portmann, B., see De Sousa, J.M.M., 28 Liaw, Y.-F., Dong, J.-T., Chiu, K.-W., Mosnier, H., see Pelletier, G., 327 Posner, M.P., see Shiffman, M.L., 351 Sheen, I.-S. and Chu, C.-M., Why most Muraca, M., see Nassuato, G., 290 Poulsen, H.E., See Fischer-Nielsen, A., patients with hepatitis delta virus infec- Mutin, M., see Krawitt, E.L., 190 110 tion are seronegative for hepatitis B e Pregliasco, F., see Bortolotti, F., 176 antigen? A prospective controlled study, Naber, A.H.J., Van Haelst, U. and Yap, Prieto, J., see Quiroga, J., 170 106 S.H., Nodular regenerative hyperplasia Prieto, J., see Quiroga, J., 302 Lieber, C.S. and DeCarli, L.M., Hepato- of the liver: an important cause of portal Pujol, P., see Rossi, V., 283 toxicity of ethanol, 394 hypertension in non-cirrhotic patients, Lieber, C.S., see Tanaka, Y., 344 94 Quiroga, J., Rodriguez-Sanroman, J.L., Ligabue, A., see Bernardi, M., 207 Naccarato, R., see Farinati, F., 402 Guarner, F., Rodriguez Ortigosa, C., Lin, H.-C., see Lee, F.-Y., 236 Naccarato, R., see Floreani, A., 217 Aréjola, J.M. and Prieto, J., Inhibitors Lin, H.-C., see Lee, S.-D., 246 Nalpas, B., Driss, F., Pol, S., Hamelin, B., of the lipoxygenase arachidonic acid Lirussi, F., see Nassuato, G., 290 Housset, C., Brechot, C. and Berthelot, pathway impair glycocholate efflux in Lo, K.-J., see Lee, F.-Y., 236 P., Association between HCV and HBV isolated rat hepatocytes, 302 412 Quiroga, J., Zozaya, J.M., Labarga, P., E., Spezia, C., Bramato, C. and Soran- ni, J.-M., Carnot, F. and Berthelot, P., Rodriguez-Ortigosa, C.M., Milazzo, A. zo, M.L., Serological diagnosis of hep- Etoposide (VP 16-213) induced hep- and Prieto, J., Renal prostacyclin influ- atitis B and delta virus (HBV/HDV) co- atitis. Report of three cases following ences renal function in non-azotemic cir- infection, 10 standard-dose treatments, 36 rhotic patients treated with furosemide, Salvagnini, M., see Farinati, F., 402 Trepo, C., see Krawitt, E.L., 190 170 Sauerbruch, T., see Kleber, G., 373 Trevisani, F., see Bernardi, M., 207 Quiroga, J.A., see Ruiz-Moreno, M., 265 Schalm, S.W., see Berk, L., 405 Triger, D.R., Endotoxemia in liver dis- Schiff, E.R., see Silva, M.O., 312 ease-time for re-appraisal, 136 Rajender Reddy, K., see Silva, M.O., 312 Schifter, S., see Bendtsen, F., 118 Trinchet, J.-C., Hartmann, D.J., Pateron, Ramadori, G., see Rieder, H., 268 Schwartzman, M.L., see Sacerdoti, D., D., Laarif, M., Callard, P., Ville, G. and Rambaud, J.C., see Colombel, J.F., 145 230 Beaugrand, M., Serum type I collagen Rambausek, M., see Kallinowski, B., 404 Sheen, I.-S., see Liaw, Y.-F., 106 and N-terminal peptide of type III pro- Raymond, J.-M., see Pelletier, G., 327 Sheron, N., Lau, J., Daniels, H., Goka, J., collagen in chronic hepatitis. Relation- Ribero, M.L., see Bortolotti, F., 176 Eddleston, A., Alexander, G.J.M. and ship to liver histology and conventional Rieder, H., Ramadori, G. and Meyer zum Williams, R., Increased production of liver test, 139 Biischenfelde, K.-H., The role of eicosa- tumour necrosis factor alpha in chronic Trinchet, J.C., see Mal, F., 45 noids in the acute phase response, 268 hepatitis B virus infection, 241 Trépo, C., see Zoulim, F., 150 Rizzardini, M., see Cuomo, R., 87 Shields, R., see Jenkins, S.A., 296 Tsai, Y.-T., see Lee, F.-Y., 236 Rizzoli, R., see Cuomo, R., 87 Shiffman, M.L., Carithers, R.L., Jr., Pos- Tsai, Y.-T., see Lee, S.-D., 246 Roda, E., see Cuomo, R., 87 ner, M.P. and Moore, E.W., Recovery Rodino, S., see Cuomo, R., 87 of bile secretion following orthotopic Vaerman, J.P., see Colombel, J.F., 145 Rodriguez-Ortigosa, C., see Quiroga, J., liver transplantation, 351 Vallebona, E., see Faa, G., 14 302 Sikuler, E., B-Adrenergic blockers for por- Valtentin, S., see Rossi, V., 283 Rodriguez-Ortigosa, C.M., see Quiroga, tal hypertension. Lessons from animal Van Damme, B., see Faa, G., 75 J., 170 model, 133 Van Eyken, P., see Faa, G., 14 Rodriguez-Sanroméan, J.L., see Quiroga, Silva, M.O., Roth, D., Rajender Reddy, Van Eyken, P., see Faa, G., 75 J., 302 K., Fernandez, J.A., Albores-Saavedra, Van Haelst, U., see Naber, A.H.J., 94 Rolandi, E., see Barreca, T., 40 J. and Schiff, E.R., Hepatic dysfunction Van den Oord, J.J., see Volpes, R., 195 Rolando, N., Harvey, F., Brahm, J., Phil- accompanying acute cocaine intoxica- Villa, E., see Levrero, M., 60 pott-Howard, J., Alexander, G., Case- tion, 312 Ville, G., see Trinchet, J.-C., 139 well, M., Fagan, E. and Williams, R.., Simoni, P., see Cuomo, R., 87 Vitvitski, L., see Zoulim, F., 150 Fungal infection: a common, unrecog- Smedile, A., see Salassa, B., 10 Volpes, R., Van den Oord, J.J., De Vos, nised complication of acute liver failure, Soranzo, M.L., see Salassa, B., 10 R., Depla, E., De Ley, M. and Desmet, 1 Spezia, C., see Salassa, B., 10 V.J., Expression of interferon-y recep- Romano, M., see Caporaso, N., 367 Spinelli, G., see Colombo, P., 64 tor in normal and pathological human Rosina, F., see Salassa, B., 10 Steinhoff, G., The potential risk of HLA liver tissue, 195 Rossi, V., Calés, P., Burtin, P., Charneau, matching after liver transplantation, 403 Volta, U., see Cassani, F., 269 J., Person, B., Pujol, P., Valtentin, S., Stockholm, K.H., see Malchow-Moller, Vyberg, M., see Junge, J., 83 D’Aubigny, N., Joubaud, F. and Boyer, A., 321 J., Prevention of recurrent variceal Strazzabosco, M., see Nassuato, G., 290 Wang, S.-S., see Lee, F.-Y., 236 bleeding in alcoholic cirrhotic patients: Svendsen, L.B., see Junge, J., 83 Williams, R., see De Sousa, J.M.M., 28 prospective controlled trial of proprano- Williams, R., see Deakin, C.D., 251 lol and sclerotherapy, 283 Tagger, A., see Bortolotti, F., 176 Williams, R., see Kalayci, C., 54 Roth, D., see Silva, M.O., 312 Tagger, A., see Levrero, M., 60 Williams, R., see Naoumov, N.V.,382 Rougier, P., see Zoulim, F., 150 Taliani, G., Lecce, R., Clementi, C., Fur- Williams, R., see Rolando, N., 1 Ria, M.J., see Ruiz-Moreno, M., 265 lan, C. and De Bac, C., Antibodies to Williams, R., see Sheron, N., 241 Rubboli, A., see Bernardi, M., 207 hepatitis C virus and response to inter- Witt, K., see Malchow-Moller, A., 321 Ruiz-Moreno, M., Ria, M.J. Carreno, V., feron treatment in non-A, non-B chronic Wu, J.-C., see Lee, S.-D., 246 Quiroga, J.A., Manns, M. and Meyer hepatitis, 264 zum Biischenfelde, K.-H., Autoimmune Tanaka, Y., Funaki, N., Mak, K.M., Kim, Yap, S.H., see Naber, A.H.J., 94 chronic hepatitis type 2 manifested dur- C.-i. and Lieber, C.S., Effects of ethanol ing interferon therapy in children, 265 and hepatic vitamin A on the prolifer- Zambello, R., see Pontisso, P., 203 Ruvoletto, M.G., see Pontisso, P., 203 ation of lipocytes in regenerating rat Zannier, A., see Krawitt, E.L., 190 liver, 344 Zauli, D., see Cassani, F., 269 Sacerdoti, D., Escalante, B.A., Schwartz- Theilmann, L., see Kallinowski, B., 404 Zoli, M., see Marchesini, G., 267 man, M.L., Abraham, N.G., Gatta, A. Thompson, G.G., see Herrick, A.L., 50 Zoulim, F. Vitvitski, L., Bouffard, P., Pi- and McGiff, J.C., Renal cytochrome P- Thomsen, C., see Malchow-Moller, A., choud, C., Rougier, P., Lamelin, J.P. 450 dependent metabolism of arachidon- 321 and Trépo, C., Detection of pre-S, pro- ic acid in cirrhotic rats, 230 Tong, M.J., see Lee, S.-D., 246 teins in peripheral blood mononuclear Salassa, B., Daziano, E., Bonino, F., La- Touraine, J.-L., see Krawitt, E.L., 190 cells from patients with HBV infection, varini, C., Smedile, A., Chiaberge, E., Tourani, J.-M., see Tran, A., 36 150 Rosina, F., Brunetto, M.R., Pessione, Tran, A., Housset, C., Boboc, B., Toura- Zozaya, J.M., see Quiroga, J., 170 Journal of Hepatology, 1991; 12: 413-414 Elsevier Science Publishers B.V . 0168-8278/91/$03.50 © 1991 Subject Index (Vol. 12) Acetaldehyde, 394 Chronic active hepatitis, 190 HDV, 64 Acute hepatitis, 176 Chronic cholestasis, 14 -, 367 Acute renal failure, 312 Chronic hepatitis, 139 Hemodynamic, 157 Adenomatosis, 28 -, 150 Hepatic necrosis, 312 Adhesion molecule, 195 Cirrhosis, 100 Hepatic C virus,70 Adults and Children, 386 -, 110 Hepatitis B, 190 AL amyloidosis, 75 -, 118 Hepatitis B e antigen, 246 Alcohol, 162 -, 162 Hepatitis B virus DNA, 246 Alcohol abuse, 367 -, 230 Hepatitis B virus, 10 Alcoholic hepatitis, 162 -, 236 -, 150 Alcoholic liver disease, 70 —, 283 -, 203 -, 83 -, 40 -, 54 Amyloidosis, 75 -, 45 -, 70 Anti-fungal therapy, 1 -, 54 Hepatitis C virus (HCV), 176 Anti-NCV, 279 —, 394 -, 279 -, 377 Community acquired hepatitis, 176 -, 377 Anti-HD, 10 Cramp, 236 Hepatitis C, 197 Anti-M2, 21 Cytochrome P-450, 110 Hepatitis D antigen, 10 Anti-M4, 21 -, 230 Hepatitis D virus RNA, 10 Anti-M8, 21 —, 336 Hepatitis delta virus, 10 Anti-M9, 21 Cytology, 256 Hepatitis, 190 Antibody to HCV, 176 Cytoxic cell, 332 Hepatitis acute, 10 Antimitochondrial antibody profile, 21 Hepatitis D, 64 Antineoplastic agent, 36 Desmin, 344 Hepato-renal syndrome, 230 Antipyrine plasma clearance, 110 Diagnosis, 256 Hepatocellular carcinoma, 367 a,-Antitrypsin deficiency, 372 Diet, 224 -, 54 Arachidonic acid metabolite, 302 Differential diagnosis, 321 -, 70 Arachidonic acid, 230 Diltiazem, 251 Hepatocellular modulation, 195 Ascites, 230 -, 36 Hepatocellular necrosis, 36 -, 45 Ductopenia, 14 Hepatotoxicity, 36 —, 94 —, 394 Aspergillus, 1 Esophageal varice, 100 Hexachlorobenzene, 87 Ethanol, 344 High density lipoprotein, 162 Balloon tamponade, 100 Ethoxycoumancin-O-deethylase, 336 HIV, 150 Betaxolol, 157 Ethoxyresorufin-O-deethylase, 336 HLA, 190 Bile acid sulfotransferase, 336 Etoposide, 36 HMG-COA reductase, 290 Bile duct destruction, 14 External shock-wave lithotripsy, 327 Human hepatocyte culture, 336 Bile duct obstruction, 321 Bile infarct, 75 Fatty liver, 224 Idiopathic adulthood ductopenia, 14 Bile saturation index, 290 -, 394 IgM anti-HD, 10 Bile secretion, 351 Fibrosis, 83 Immunohistochemistry, 195 Bile, 87 Firbolammelar hepatoma, 54 -, 54 Biliary excretion, 87 Fungal infection, 1 -, 372 Biliary lipids, 290 Furosemide, 170 Immunology, 256 Bromodeoxyuridine, 344 Immunosuppressive drug, 94 Budd-Chiari syndrome, 28 Galactose elimination capacity, 110 Insulin, 40 Gallstone patient, 290 Interferon-y receptor, 195 C-peptide, 40 Gallstone, 327 Interferon-y, 195 C3 concentration, 45 Gene amplification, 64 Intracellular calcium, 251 Calcitonin gene-related peptide (CGRP), Glucagon, 40 Intrahepatic cholestasis, 75 118 Glutathione, 110 Isolated rat hepatocyte, 302 Calcitonin, 217 Glutathione S-transferase, 336 Candida, 1 Glycocholate transport, 302 Jaundice, 321 Capacity of urea-N synthesis, 110 Granular lymphocytes, large (LGL), 332 Carbon tetrachloride, 251 Growth factor, 316 Karyotypic, 332 CC1,, 110 Kidney transplantation, 94 Cell death, 251 Haemorrhage, 296 Kidney, 230 Chemoattractant activity, 45 HBV, 64 Choleretic index, 351 -, 367 Lecithin, 394 Cholestasis, 75 HBV-DNA, 64 Light chain deposition disease, 75 Chronic active hepatitis B, 246 HCV, 367 Lipocyte, 344 414 Lipopolysaccharide, 162 Obesity, 224 Results, 386 Lipoxygenase, 302 Observer variation, 321 Rhabdomyolysis, 312 Liver biopsy, 256 Oesophageal variceal pressure, 362 Liver cirrhosis, 170 Oesophagitis, 296 S-Adenosyl-Lmethionine, 87 Liver disease, 64 Opsonic activity, 45 -, 394 —, 94 Oral bile acid therapy, 327 Sclerotherapy, 100 -, 336 Organ extraction, 118 -, 283 Liver failure, 1 Osteodystrophy, 217 —, 296 -, 312 Secondary prevention, 283 Liver fibrosis, 224 Paracetamol, 251 Selection, 386 -, 139 Partial hepatectomy, 316 Serum alanine aminotransferase, 139 -, 367 Pathogenesis, 28 Serum y-globulin, 139 Liver function test, 256 Paucity of intrahepatic bile ducts, 14 Serum markers of collagen metabolisms, Liver function, 110 Pentobarbital, 157 139 Liver growth, 316 Peripheral blood cell, 203 Serum N-terminal peptide of type III pro- Liver inflammation, 195 Peripheral blood mononuclear cell, 150 collagen, 139 -, 224 Phenotype, Piz, 372 Serum type I collagen, 139 Liver physiopathology, 224 Phenotype, PiM link, 372 Silibin, 290 Liver regeneration, 316 Piezoelectric lithotripsy, 327 Sinusoidal congestion, 28 -, 344 Pig liver, 316 Somatostatin, 100 Liver sinusoid, 332 PiM Cagliari, 372 —, 296 Liver transplantation, 256 Polymerase chain reaction, 279 -, 40 -, 332 Porphyria, 87 Splanchic circulation, 157 -, 351 Porphyrin, 87 Spontaneous bacterial peritonitis, 45 --, 386 Portal hypertension, 100 Steroid, 246 Liver, 190 -, 157 -, 372 -, 162 Test meal, 40 -, 28 -, 362 Total protein concentration, 45 Lower oesophageal sphincter, 362 -, 94 Lymphocyte, 190 Post-transfusion hepatitis, 377 Ulcer, 296 Lymphokine, 195 Pre-S protein, 203 Ultrasound diagnosis, 321 Pre-S, protein, 150 Upper gastrointestinal bleeding, 100 Malignant peritonitis, 45 Primary biliary cirrhosis, 21 Metoclopramine, 362 -, 217 Varice, 94 Mixed function oxidase, 336 Prognosis, 21 Variceal bleeding, 100 Mucosal invasion, 1 Propanolol, 283 —, 283 Prostacyclin, 170 Verapamil, 251 Natriuresis, 170 Prostaglandin E,, 170 Viral attachment, 203 Natural killer cell, 332 Viral hepatitis, 176 Nicardipine, 251 Quinidine, 236 -, 279 Nifedipine, 251 Quinine, 236 Viral replication, 150 Nodular regenerative hyperplasia, 28 -,94 — ,64 Radiology, 256 Virus DNA, 64 Non-A, non-B hepatitis, 176 Rat liver, 316 Vitamin A, 344 Normal human liver, 336 Rejection, 256 Nutrition, 394 Renal function, 170 Western blot, 150 Obesity treatment, 224